Zepatier
(Grazoprevir)Phase 3Small molecule
Merck & Co.Grazoprevir is used to treat hepatitis C, a viral infection that damages the liver. It works by stopping the hepatitis C virus from reproducing in the body.[1] Zepatier is currently being investigated across 7 indications[3], with its most advanced program in Phase 3.[1]
Zepatier is one of 234 small molecule programs targeting Viral Disease. It is currently in Phase 3.
7
Indications
26
Total Trials
0
Active Trials
233
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
624 competitors in Chronic Hepatitis
#DrugCompanyPhaseTrials
1Zepatier
Merck & Co.Phase 3
PEG-Intron
Merck & Co.Preclinical
Sovaldi
GileadPreclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Incivek
Vertex PharmaceuticalsPreclinical
Intron a
SanofiPreclinical
Roferon-a
RochePreclinical
Medrol
PfizerPreclinical
Dasabuvir
AbbViePreclinical
SOF/VEL
GileadPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis17 trials
Show 14 more trials
Hepatitis C5 trials
Show 2 more trials
Hepatic Insufficiency1 trial
Renal insufficiency1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Grazoprevir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company